A Randomized, Double Blind, Parallel-group, Dose Escalation Placebo-controlled Multicenter Study to Investigate the Safety and Tolerability of IBP-9414 Administered in Preterm Infants.

Trial Profile

A Randomized, Double Blind, Parallel-group, Dose Escalation Placebo-controlled Multicenter Study to Investigate the Safety and Tolerability of IBP-9414 Administered in Preterm Infants.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs Lactobacillus reuteri (Primary)
  • Indications Acute enterocolitis
  • Focus Adverse reactions
  • Sponsors Infant Bacterial Therapeutics
  • Most Recent Events

    • 28 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 11 Dec 2017 Results published in an Infant Bacterial Therapeutics Media Release
    • 11 Dec 2017 Data from this trial were presented at the Hot Topics in Neonatology Conference 2017, as reported in an Infant Bacterial Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top